Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

Published Date: 01 Mar 2024

Phase I study patients with different solid tumors had an objective response rate of 37.7%.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An understudied type of breast cancer poses a lurking threat

2.

A study suggests that screening for liver cancer is beneficial for patients with cirrhosis.

3.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

4.

Mezigdomide Combinations Show Promise in Multiple Myeloma

5.

New imaging technique identifies glioblastoma patients who would benefit from immunotherapy


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot